Longevity health holdings announces continued nasdaq listing to complete merger with 20/20 biolabs

Pittsburgh, may 21, 2025 (globe newswire) -- longevity health holdings, inc. (nasdaq: xage) (“xage,” the “company,” “we,” “us,” or “our”), a company focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition, today announced that it has received a favorable decision from the nasdaq hearings panel (the “panel”) granting the company's request to continue its listing on the nasdaq stock market (“nasdaq”) subject to the satisfaction of the nasdaq initial listing rules for the combined company following the proposed merger with 20/20 biolabs, inc. (“20/20”) on or before september 2, 2025. this decision follows the panel's comprehensive review of the company's recent business developments, financial disclosures, and proposed merger with 20/20.
XAGE Ratings Summary
XAGE Quant Ranking